论文部分内容阅读
目的:观察依达拉奉治疗急性脑梗死的疗效。方法:选择诊断明确的急性脑梗死患者102例。治疗组在常规治疗基础上给予依达拉奉治疗14 d。治疗前及14 d后,按临床神经功能缺损程度评分标准,进行临床疗效评定。结果:治疗组14 d后神经功能缺损评分明显低于对照组,总有效率明显高于对照组。结论:依达拉奉治疗急性脑梗死安全有效。
Objective: To observe the therapeutic effect of edaravone on acute cerebral infarction. Methods: A total of 102 patients with acute cerebral infarction were selected. The treatment group was treated with edaravone on the basis of routine treatment for 14 days. Before treatment and after 14 days, according to the clinical neurological deficit score standards, clinical efficacy evaluation. Results: After 14 days, the neurological deficit score of the treatment group was significantly lower than that of the control group, and the total effective rate was significantly higher than that of the control group. Conclusion: Edaravone is safe and effective in treating acute cerebral infarction.